Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · BriaCell Therapeutics Corp. (BCTX)

BriaPro nine-month net loss widens to $712,236; going concern doubt remains

Negative Impact 3 of 5 earnings Written later

BriaPro Therapeutics, a subsidiary of BriaCell Therapeutics, filed unaudited financial statements for the three and nine months ended April 30, 2026, with Canadian regulators. The nine-month net loss rose to $712,236 from $519,804 a year earlier, and the filing states a material uncertainty about the company's ability to continue as a going concern, with BriaCell as its only stated financing source until it raises more capital.

Key points

  • Nine-month net loss of $712,236 versus $519,804 for the same period a year earlier; three-month net loss narrowed to $240,005 from $286,619
  • Cash of $299,950 at April 30, 2026, including a $300,000 related-party advance from BriaCell; negative working capital of $1,937,495
  • Amounts owed to BriaCell group companies totaled $2,093,345; the monthly service fee was reduced from $20,000 to $5,000 effective April 30, 2026
  • On March 31, 2026, the company acquired the sCD80 license from BriaCell for 23,972,589 common shares valued at $846,532

The filing

CompanyBriaCell Therapeutics Corp. (BCTX)
Form8-K, current report
Filed with the SECJun 26, 2026, 4:05 PM ET
Accession number0001493152-26-030286

Items reported: 7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on June 26, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.